Trevena, Inc. (TRVN): Price and Financial Metrics


Trevena, Inc. (TRVN): $0.28

0.03 (+12.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TRVN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TRVN POWR Grades


  • TRVN scores best on the Sentiment dimension, with a Sentiment rank ahead of 75.86% of US stocks.
  • The strongest trend for TRVN is in Quality, which has been heading down over the past 176 days.
  • TRVN's current lowest rank is in the Quality metric (where it is better than 3.96% of US stocks).

TRVN Stock Summary

  • TRVN's price/sales ratio is 119.84; that's higher than the P/S ratio of 97.89% of US stocks.
  • Revenue growth over the past 12 months for Trevena Inc comes in at -78.98%, a number that bests only 1.42% of the US stocks we're tracking.
  • The volatility of Trevena Inc's share price is greater than that of 94.42% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Trevena Inc, a group of peers worth examining would be ICAD, SSYS, MBII, HTGM, and PLAB.
  • Visit TRVN's SEC page to see the company's official filings. To visit the company's web site, go to www.trevena.com.

TRVN Valuation Summary

  • In comparison to the median Healthcare stock, TRVN's price/sales ratio is 453.3% higher, now standing at 62.8.
  • Over the past 92 months, TRVN's price/earnings ratio has gone up 3.8.
  • Over the past 92 months, TRVN's EV/EBIT ratio has gone up 3.1.

Below are key valuation metrics over time for TRVN.

Stock Date P/S P/B P/E EV/EBIT
TRVN 2021-08-31 62.8 2.4 -5.3 -3.2
TRVN 2021-08-30 60.0 2.3 -5.0 -3.0
TRVN 2021-08-27 61.9 2.4 -5.2 -3.1
TRVN 2021-08-26 58.1 2.2 -4.9 -2.8
TRVN 2021-08-25 60.4 2.3 -5.1 -3.0
TRVN 2021-08-24 58.5 2.2 -4.9 -2.9

TRVN Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at 57.74%.
  • Its year over year revenue growth rate is now at 10474.19%.
  • The 3 year net cashflow from operations growth rate now stands at 58.58%.
TRVN's revenue has moved up $606,000 over the prior 15 months.

The table below shows TRVN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 0.637 -44.713 -49.506
2021-06-30 3.456 -35.523 -41.286
2021-03-31 3.278 -29.173 -33.486
2020-12-31 3.069 -21.394 -29.369
2020-09-30 3.031 -21.067 -23.943
2020-06-30 0.031 -24.505 -26.958

TRVN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TRVN has a Quality Grade of C, ranking ahead of 33.81% of graded US stocks.
  • TRVN's asset turnover comes in at 0.029 -- ranking 357th of 680 Pharmaceutical Products stocks.
  • SIGA, FBRX, and INFI are the stocks whose asset turnover ratios are most correlated with TRVN.

The table below shows TRVN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.029 0.826 -3.505
2021-03-31 0.030 0.895 -2.700
2020-12-31 0.035 0.941 -2.283
2020-09-30 0.044 1.000 -1.557
2020-06-30 0.001 1.000 -1.390
2020-03-31 0.001 1.000 -0.927

TRVN Price Target

For more insight on analysts targets of TRVN, see our TRVN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.25 Average Broker Recommendation 1.62 (Moderate Buy)

TRVN Stock Price Chart Interactive Chart >

Price chart for TRVN

TRVN Price/Volume Stats

Current price $0.28 52-week high $2.20
Prev. close $0.25 52-week low $0.18
Day low $0.25 Volume 1,273,800
Day high $0.28 Avg. volume 1,119,991
50-day MA $0.36 Dividend yield N/A
200-day MA $0.72 Market Cap 46.01M

Trevena, Inc. (TRVN) Company Bio


Trevena Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and intent to commercialize therapeutics for G protein coupled receptors. The company was founded in 2007 and is based in King of Prussia, Pennsylvania.


TRVN Latest News Stream


Event/Time News Detail
Loading, please wait...

TRVN Latest Social Stream


Loading social stream, please wait...

View Full TRVN Social Stream

Latest TRVN News From Around the Web

Below are the latest news stories about Trevena Inc that investors may wish to consider to help them evaluate TRVN as an investment opportunity.

Trevena to Present at the 2022 BIO CEO & Investor Conference

CHESTERBROOK, Pa., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO, will present a corporate overview at the BIO CEO & Investor Conference being held from February 14th - 17th, 2022. Additional Conference Details Format:Pre-recorded corporate presentation and one-on-one virtua

Yahoo | February 3, 2022

Trevena Submits NDA for OLINVYK Injection in China

Trevena, Inc.(Nasdaq: TRVN) disclosed that it has submitted a New Drug Application for OLINVYK (oliceridine) injection, designed to treat acute pain in adults, to China’s National Medical Products Administration (NMPA). The biopharmaceutical company focuses on the development of treatment for diseases affecting the central nervous system. Shares of the company declined 5.4% on Thursday but gained 10.4% in the extended trading session. The application was submitted by Trevena’s partner, Jiangsu Nhwa Pharmaceutical, post-completion of a Phase 3 bridging trial for OLINVYK. Notably, the injection has already been approved by the U.S. Food and Drug Administration.

Radhika Saraogi on TipRanks | January 28, 2022

Lab Notes: AmerisourceBergen teams with UK tech firm; Chimeron Bio relocates to Center City

News out of Greater Philadelphia's life sciences industry this week includes a pharmaceutical packaging partnership, a cell and gene therapy distribution alliance, a lease deal, a gene therapy candidate, and more. Here's the roundup: West Pharmaceutical Services The Exton-based designer and manufacturer of injectable pharmaceutical packaging and delivery systems entered into an exclusive supply and technology agreement with specialty glass and materials maker Corning Inc. According to the companies, the deal will facilitate a multimillion-dollar capital and research and development investment to expand work on Corning's Valor glass technology and to produce advanced injectable drug packaging and delivery systems for the pharmaceutical industry.

Yahoo | January 28, 2022

Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical

Submission supported by data from a Phase 3 bridging study of oliceridine injection compared to IV morphine, conducted in China by Nhwa Trevena is eligible to receive future success payments upon approval and commercialization milestones, as well as a 10% royalty on net sales in China CHESTERBROOK, Pa., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous s

Yahoo | January 27, 2022

Trevena to Participate in the Upcoming January Conferences

CHESTERBROOK, Pa., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO and Barry Shin, Chief Financial Officer, will be participating in three January virtual investor and partnering conferences, with additional details below. Conference Details LifeSci Partners - 11th Annual Corp

Yahoo | January 3, 2022

Read More 'TRVN' Stories Here

TRVN Price Returns

1-mo -9.47%
3-mo -40.93%
6-mo -59.91%
1-year -83.91%
3-year -76.86%
5-year -89.89%
YTD -51.93%
2021 -72.78%
2020 154.49%
2019 95.56%
2018 -73.13%
2017 -72.79%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4901 seconds.